Modulation by female sex hormones of the cannabinoid-induced catalepsy and analgesia in ovariectomized mice.
Cannabinoids are psychoactive compounds with many pharmacological properties such as analgesia, sedation and catalepsy most of which are mediated by cannabinoid CB1 receptors. In the present study, we evaluated whether the ovarian sex hormones are involved in the cannabinoid-induced catalepsy and analgesia in ovariectomized female mice. Female NMRI mice (weighing 25-30 g) were divided into 3 main groups: unoperated, sham-operated and ovariectomized. Both the catalepsy and analgesia induced by different doses of the synthetic cannabinoid WIN 55,212-2 (2 and 4 mg/kg, i.p.) were examined in the groups in the presence or absence of the cannabinoid CB1 antagonist AM251 (0.5 mg/kg). We also evaluated effects of estradiol valerate (10 mg/kg) and progesterone (25 mg/kg) on catalepsy and analgesia induced by WIN 55,212-2 in ovariectomized mice. The antinociceptive effect of WIN 55,212-2 was significantly (P<0.01) enhanced in ovariectomized mice, which was prevented by pretreatment with estradiol but not by progesterone. There was no significant difference in the cannabinoid-induced catalepsy between control and ovariectomized mice. However, pretreatment with progesterone but not estradiol potentiated the cataleptic effect of low dose of WIN 55,212-2 (2 mg/kg) in ovariectomized mice (P<0.01). The present data demonstrated for the first time that ovarian sex steroids could modulate both cannabinoid-induced catalepsy and analgesia in female ovariectomized mice.
Kalbasi  Anaraki
Dina
D
Department of Pharmacology, School of Medicine, Medical Sciences/University of Tehran, P.O. Box: 13145-784, Tehran, Iran.
Sianati
Setareh
S
Sadeghi
Mahsa
M
Ghasemi
Mehdi
M
Paydar
Mehrak Javadi
MJ
Javadi
Parvin
P
Ejtemaei Mehr
Shahram
S
Dehpour
Ahmad Reza
AR
D000700:Analgesics / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D048588:Benzoxazines / Q000494:pharmacology; D002186:Cannabinoids / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000633:toxicity*; D002375:Catalepsy / Q000139:chemically induced* / Q000517:prevention & control* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006358:Hot Temperature; D051379:Mice; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D010052:Ovariectomy; D010147:Pain Measurement / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology
D000700:Analgesics; D048588:Benzoxazines; D002186:Cannabinoids; D004967:Estrogens; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; C103505:AM 251; D011374:Progesterone; D004958:Estradiol; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone